XML 61 R28.htm IDEA: XBRL DOCUMENT v2.4.0.8
Fair Value Measurements (Tables)
 3 Months Ended 6 Months Ended
Jun. 30, 2013
Jun. 30, 2013
Fair Value Measurements [Abstract]    
Fair Value, Assets Measured on Recurring Basis, Unobservable Input Reconciliation [Table Text Block]
For those financial instruments with significant Level 3 inputs, the following table summarizes the activity for the three and six months ended June 30, 2013 by type of instrument (in thousands):
 
 
Three Months Ended
 
Six Months Ended
 
June 30, 2013
 
June 30, 2013
 
Warrants
 
Contingent Consideration
 
Warrants
 
Contingent Consideration
Beginning liability balance
$
90.6

 
$
7,550.0

 
$
101.2

 
$
7,550.0

Change in fair value recorded in earnings
(58.0
)
 
—

 
(68.6
)
 
—

Ending liability balance
$
32.6

 
$
7,550.0

 
$
32.6

 
$
7,550.0

  
Fair Value, Assets and Liabilities Measured on Recurring and Nonrecurring Basis, Valuation Techniques [Table Text Block]  

The Company also determined the fair value of contingent consideration, initially recognized on October 17, 2011 in connection with the Company's acquisition of Amorcyte, to be level 3 inputs. The fair value of contingent consideration obligations is based on a discounted cash flow model using a probability-weighted income approach. The measurement is based upon unobservable inputs supported by little or no market activity based on our own assumptions and experience. The value of our contingent consideration was initially calculated using a discount rate of 30%. We base the timing to complete the development and approval of this product on the current development stage of the product and the inherent difficulties and uncertainties in developing a product candidate, such as obtaining U.S. Food and Drug Administration (FDA) and other regulatory approvals. In determining the probability of regulatory approval and commercial success, we utilize data regarding similar milestone events from several sources, including industry studies and our own experience. These fair value measurements represent Level 3 measurements as they are based on significant inputs not observable in the market. Significant judgment is employed in determining the appropriateness of these assumptions as of the acquisition date and for each subsequent period. Accordingly, changes in assumptions could have a material impact on the amount of contingent consideration expense we record in any given period. Changes in the fair value of the contingent consideration obligations are recorded in our consolidated statement of operations.

The following table sets forth by level within the fair value hierarchy the Company’s financial assets and liabilities that were accounted for at fair value on a recurring basis as of June 30, 2013, and December 31, 2012 (in thousands):
 
 
June 30, 2013
 
Fair Value Measurements Using Fair Value Hierarchy
 
Level 1
 
Level 2
 
Level 3
Warrant derivative liabilities
$
—

 
$
—

 
$
32.6

Contingent consideration
—

 
—

 
7,550.0

 
 
December 31, 2012
 
Fair Value Measurements Using Fair Value Hierarchy
 
Level 1
 
Level 2
 
Level 3
Warrant derivative liabilities
$
—

 
$
—

 
$
101.2

Contingent consideration
—

 
—

 
7,550.0